MicroVention, Inc.
$8.4M 4,847 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
PTC Therapeutics, Inc.
PTC Therapeutics, Inc. reported $8,364,044.19 across General Payments, Research, and Ownership to 505 physicians and teaching hospitals across 1,680 transactions.
- $8.4M Top quartile payer
- All-tracks total
- 1,680 Top quartile volume
- Transactions
- 505 Above-median reach
- Recipients
- −$146.1K
- General Payments vs PY2023
PTC Therapeutics, Inc. reported $8,364,044.19 across all CMS Open Payments tracks (General + Research + Ownership) to 505 physicians and teaching hospitals in Program Year 2024 - ranking #203 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $464,150.06, averaging $16.6K per recipient.
How PTC Therapeutics, Inc.'s $8.4M all-tracks total breaks down
PTC Therapeutics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
56/100
Total payments
B
87/100
Transaction volume
F
22/100
Physician reach
F
14/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ptc-therapeutics-inc PTC Therapeutics, Inc.
$8.4M · #203/1,925 · 0.1% industry · PY2024
- TOT $8.4M
- RANK #203
- SHARE 0.1%
- TXN 1,680
- RCP 505
- CAT 8
- GEN $464.2K
- ΔGEN −$146.1K
- TOP1 19.4%
- PY 2024
Volume peers
Nearest volume peer: MicroVention, Inc. ($8.4M)
PTC Therapeutics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
PTC Therapeutics, Inc.'s CMS-reported General Payments decreased by $146.1K (−23.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PTC THERAPEUTICS, INC.PY2023: PTC THERAPEUTICS, INC.PY2024: PTC Therapeutics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $610,267.96
- PY2024
- $464,150.06
What the Data Shows for PTC Therapeutics, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For PTC Therapeutics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 8-category general-payment breakdown below at $219.3K (47.2% of General Payments, 56 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads PTC Therapeutics, Inc.'s 8-category general-payment breakdown at $219.3K, 47.2% of the reported total.
PTC Therapeutics, Inc. reports 8 general-payment categories - the top three are Consulting Fee (47.2%), Travel and Lodging (25.4%), and Compensation for Services Other Than Consulting (21.5%). The remaining 5 categories make up 5.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: PTC Therapeutics, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How PTC Therapeutics, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $219.3K | 56 | 47.2% |
| Travel and Lodging | $118.1K | 120 | 25.4% |
| Compensation for Services Other Than Consulting | $99.9K | 25 | 21.5% |
| Food and Beverage | $11.0K | 290 | 2.4% |
| Space Rental or Facility Fees | $7.0K | 4 | 1.5% |
| Royalty or License | $5.0K | 1 | 1.1% |
| Education | $2.9K | 8 | 0.6% |
| Grant | $1.0K | 1 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $243,062.03 (52.4%) of $464,150.06 in this company's General Payments records across 140 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for PTC Therapeutics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Glenn Steele
$90,185.83 across 56 reported transactions
- 2
Massachusetts General Hospital
$70,747.32 across 4 reported transactions
- 3
Daniel Claassen
$29,593.45 across 18 reported transactions
- 4
Nicola Longo
$27,436.79 across 18 reported transactions
- 5
Melissa Lah
$25,098.64 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
PTC Therapeutics, Inc. ranks #203 of 1,925 by total payments (top 11% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,111 of 1,838 by HHI (bottom 40% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Arcuro Medical Inc : $38.4K total payments, HHI 830
- Day One Biopharmaceuticals : $191.7K total payments, HHI 822
- Altus Partners. LLC : $374.7K total payments, HHI 817
- SIGN Fracture Care International : $6.8K total payments, HHI 815
- Septodont Inc. : $289.4K total payments, HHI 813
- BioHorizons Implant Systems Inc. : $1.4M total payments, HHI 813
- PTC Therapeutics, Inc. (this company) : $464.2K total payments, HHI 811
- Planmeca USA, Inc. : $214.2K total payments, HHI 810
- Elevation Spine, Inc. : $38.6K total payments, HHI 810
- Terumo Cardiovascular Systems Corporation : $22.7K total payments, HHI 809
- Pierre Fabre Pharmaceuticals, Inc. : $53.6K total payments, HHI 809
- Marinus Pharmaceuticals, Inc. : $279.2K total payments, HHI 807
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as PTC Therapeutics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about PTC Therapeutics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with PTC Therapeutics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Beckman Coulter, Inc.
$8.3M 469 recipients
Compare payment profiles
Lightforce Orthodontics, Inc.
$8.3M 2,676 recipients
Compare payment profiles
Bavarian Nordic A/S
$8.4M 37 recipients
Compare payment profiles
Genentech USA, Inc.
$8.5M 55,859 recipients
Compare payment profiles
Circinus Medical Technology LLC
$8.5M 26 recipients
Compare payment profiles
Put this to use
PTC Therapeutics, Inc. ranks #203 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where PTC Therapeutics, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just PTC Therapeutics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.